Variables determining the development of colistin-associated renal impairment

Wiener Klinische Wochenschrift

Volumn 128, Issue , 2016, Pages 614-619

  Ceylan, Bahadır ^a,c   Taniş, Müdür ^b   Akkoyunlu, Muhammed Emin ^a   Çınar, Ahmet ^a   Kurt, Ayşe Ruhkar ^a   Akkoyunlu, Yasemin ^a   Ozkan, Didem ^a   Ozcelik, Hatice Kutbay ^a   Aslan, Turan ^a   Fincancı, Muzaffer ^b   Vatansever, Şule ^b   İdin, Kadir ^a   Guler, Emine ^a   Uysal, Harun ^a  

^a BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^b ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Y ld r m Beyaz t Caddesi   (Turkey)

Author keywords

Acute renal injury; Adverse effects; Colistin; Drug induced abnormalities; Renal tubulopathy

Indexed keywords

ALBUMIN; AMINOGLYCOSIDE; AMPHOTERICIN B; BILIRUBIN; CALCINEURIN INHIBITOR; COLISTIMETHATE; CONTRAST MEDIUM; COTRIMOXAZOLE; CREATININE; NONSTEROID ANTIINFLAMMATORY AGENT; RIFAMPICIN; BIOLOGICAL MARKER; COLISTIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BILIRUBIN BLOOD LEVEL; CATHETER INFECTION; CENTRAL VENOUS CATHETER; COHORT ANALYSIS; COLISTIN ASSOCIATED RENAL IMPAIRMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; FEMALE; GLASGOW COMA SCALE; HUMAN; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; RETROSPECTIVE STUDY; RISK FACTOR; SOFT TISSUE INFECTION; SURVIVAL ANALYSIS; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VERY ELDERLY; ACUTE KIDNEY INJURY; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PREVALENCE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; COHORT STUDIES; COLISTIN; CREATININE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

EID: 84928599595     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-015-0773-z     Document Type: Article

References (39)

1. Waterer GW, Wunderink RG. Increasing threat of gram-negative bacteria. Crit Care Med. 2001;29(4):75–81.
2. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879–84.
3. Kwon JA, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents. 2010;35(5):473–7.
4. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect. 2012;65(1):80–7.
5. Durakovic N, Radojcic V, Boban A, et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011;50(9):1009–13.
6. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother. 2012;56(5):2392–6.
7. Montero M, Horcajada JP, Sorlí L, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection. 2009;37(5):461–5.
8. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents. 2009;34(5):434–8.
9. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant gram-negative bacterial infections. Int J Antimicrob Agents. 2010;35(3):297–300.
10. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010;65(5):1019–27.
11. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010;54(10):4503–5.
12. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2008;61(2):417–20.
13. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med. 2007;33(7):1162–7.
14. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36(9):1111–8.
15. Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28(5):1008–11.
16. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35(2):194–9.
17. Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007;51(6):1905–11.
18. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 2008;61(6):1369–75.
19. Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis. 2009;9:26.
20. Lim SK, Lee SO, Choi SH, et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci. 2011;26(3):325–31.
21. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP. Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother. 2011;66(1):175–9.
22. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother. 2003;47(8):2659–62.
23. Mostardeiro MM, Pereira CA, Marra AR, Pestana JO, Camargo LF. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob Agents Chemother. 2013;57(3):1442–6.
24. Hartzell JD, Neff R, Ake J, Wortmann G. et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48(12):1724–8.
25. Ko Hj, Jeon Mh, Choo Ej, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract. 2011;117(3):284–8.
26. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract. 2008;109(4):182–7.
27. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2:81–4.
28. Navarro A, Boveris A. The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol. 2007;292(2):670–86.
29. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120(4):483–95.
30. Yousef JM, Chen G, Hill PA, Nation RL, Li J. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother. 2011;55(9):4044–9.
31. Ozyilmaz E, Ebinc FA, Derici U, et al. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med. 2010;37(1):141–6.
32. Yousef JM, Chen G, Hill PA, Nation RL, Li J. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother. 2012;67(2):452–9.
33. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–41.
34. Desai TK, Tsang TK. Aminoglycoside nephrotoxicity in obstructive jaundice. Am J Med. 1988;85(1):47–50.
35. Oliveira JF, Silva JA, Barbieri CD, Oliveira GM, Zanetta DM, Burdmann EA. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009;53(7):2887–91.
36. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. J Antimicrob Chemother. 2010;65(12):2645–9.
37. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56(6):432–6.
38. Reina R, Estenssoro E, Sáenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005;31(8):1058–65.
39. Rios FG, Luna CM, Maskin B, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J. 2007;30(2):307–13.